Altamira Therapeutics Ltd
NASDAQ:CYTO
Altamira Therapeutics Ltd
Cash from Financing Activities
Altamira Therapeutics Ltd
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Altamira Therapeutics Ltd
NASDAQ:CYTO
|
Cash from Financing Activities
CHf10.6m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Novartis AG
SIX:NOVN
|
Cash from Financing Activities
-$10.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-1%
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Cash from Financing Activities
$17.4m
|
CAGR 3-Years
249%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
Roche Holding AG
SIX:ROG
|
Cash from Financing Activities
-CHf4.2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Cash from Financing Activities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Altamira Therapeutics Ltd's Cash from Financing Activities?
Cash from Financing Activities
10.6m
CHF
Based on the financial report for Dec 31, 2023, Altamira Therapeutics Ltd's Cash from Financing Activities amounts to 10.6m CHF.
What is Altamira Therapeutics Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
13%
Over the last year, the Cash from Financing Activities growth was 8%. The average annual Cash from Financing Activities growth rates for Altamira Therapeutics Ltd have been -14% over the past three years , 13% over the past five years .